Výsledky vyhledávání - "Herbert Leon Duvivier"

Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study

Publikováno v: Journal of Clinical Oncology. 41:122-122

122 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of pts with CRC with ATM mut treated with O are report

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f7ae02e5ad1df8453c2bc3339cac5b78
https://doi.org/10.1200/jco.2023.41.4_suppl.122

Zobrazit plný text záznamu

Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study

Publikováno v: Journal of Clinical Oncology. 41:546-546

546 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of pts with BTC with ERBB2/3 amp, oe, or mut treated w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::393f74b41f17f35184eb72a5924e17dc
https://doi.org/10.1200/jco.2023.41.4_suppl.546

Zobrazit plný text záznamu

First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data

Autor: Eugene R Ahn, Herbert Leon Duvivier, Drew W. Rasco, Agnes Rethy, Chris Moore, Amy Yuet, Sandra R. Hankins, Rachael Orlandella, Swati Khanna, Joseph Dekker, Angela Georgy, David R. Spigel

Publikováno v: Journal of Clinical Oncology. 40:2521-2521

2521 Background: MT-6402 is a unique and potent PD-L1-targeted engineered toxin body (ETB) capable of directly killing PD-L1 expressing tumor and immune cells by internalization of a fused Shiga-like toxin A subunit (SLTA) resulting in permanent SLTA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c9f29b7894c58cb2aeae1b6dd02bbc9e
https://doi.org/10.1200/jco.2022.40.16_suppl.2521

Zobrazit plný text záznamu

Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with high tumor mutational burden (hTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study

Autor: Gina M. Vaccaro, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Jimmy J. Hwang, Olatunji B. Alese, Maged F. Khalil, Muhammad Khurram Hameed, Herbert Leon Duvivier, Timothy Lewis Cannon, Gina N. Grantham, Susan Halabi, Richard L. Schilsky

Publikováno v: Journal of Clinical Oncology. 40:107-107

107 Background: TAPUR is a phase II basket study evaluating the anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of CRC pts with hTMB treated with N+I are reporte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2afddef128755ceb3663734562c2217f
https://doi.org/10.1200/jco.2022.40.4_suppl.107

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání